Trial · NCT06967012
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | Change in seizure frequency: The reduction in seizure frequency over an average of four weeks during the maintenance period, compared with the retrospective baseline period, in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. |
| Primary | Primary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | ≥50% response rate: The proportion of subjects achieving a ≥50% reduction in the average four-week seizure frequency during the maintenance period compared to the retrospective baseline period in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. |
| Secondary | Secondary Observational Indicators | Week 0±7day, Week 8±7day, Week 20±7day | 1. The percentage of patients achieving seizure-free status during the maintenance period in patients with focal epilepsy with or without secondary generalized tonic-clonic seizures. 2. Retention rate: The percentage of patients who continue to take the medication within a specific time compared to the initial number of patients who started the medication. |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Weight (kg) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | blood pressure (mmHg) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Pulse (bpm) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Blood routine: WBC (/L), PLT (/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Liver function: ALT (U/L), AST (U/L), ALP (U/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Kidney function: Scr(μmol/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Blood routine: Hb (g/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Kidney function: UREA(mmol/L) |
| Secondary | Safety Evaluation | Week 0±7day, Week 8±7day, Week 20±7day | Liver function: TBIL (μmol/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06967012/registered